Access to Medicine IndexProblem Statement

Long-standing debate about:

• What is the role of the pharmaceutical industry in access to medicines?

• Where are the gaps in understanding their current role?

• What are considered best-practices of companies with respect to access to medicines?

The Access to Medicine Index was established in 2005 to take an inclusive and collective approach to defining the role of the pharmaceutical industry through dialogue and consultation with all major stakeholders including the industry itself.

Access to Medicine Index A New Approach to these Problems

The Index attempts to establish best practices for companies’ behaviour and to rank company policies and practices based on the established criteria.

Access to Medicine Index 2010Study Objectives

This poster presents the process and the challenges involved in designing methodology and measuring companies for the Access to Medicine Index.

Two main areas of challenge are faced:

1. How to design a process in which a diverse array of stakeholders can constructively contribute to building a framework?

2. How to ensure a fair and meaningful assessment and comparison between companies?

Access to Medicine Index 2010Methods

Framework structure:• 107 indicators are used

to assess the companies• Structured along 2 axes

of analysis

Scope & study poulation:• 20 largest pharmaceutical

companies• Data from the 2008 & 2009

Financial Year’s• Policies & activities accross 88

countries & 33 diseases.

Access to Medicine Index 2010Results: measuring and comparing

Having established the revised assessment framework…

…how to ensure a fair and meaningful assessment and comparison between companies? Especially when there exist:

1. Variability in business models

2. High correlation between indicators?

3. Relative absence of performance data?

4. Data provision in different units and structures?

5. Challenges in measuring impact on relieving social burden?

Access to Medicine Index 2010Results: measuring and comparing

1. Variability in business models and how to reflect it in the scoring process?• Several performance indicator scores were adjusted based

on scale indicators including: – Pharmaceutical revenues– Market capital– Size of research pipeline

• Also % of revenues from originator and generics sales was an additional weight adjustment.

• ‘Portfolio breadth’ adjustments were removed in Index 2010 : ‘All companies’ contributions to access to medicines should be evaluated on the same weighting of criteria’.

Access to Medicine Index 2010Results: measuring and comparing

2. How to handle high correlation between transparency and performance indicators?

• Strategic pillars ensure the Index provides rankings along the areas stakeholders seek to influence the industry.

• In some situations indicators have a strong correlation to others in different pillars (particularly transp & perform.). • i.e. F.II.2 / F.III.2 (IC-partnerships for local capacity

building in research)• Following statistical review of Index 2010 indicators,

technical sub-committees are removing and refining indicators for Index 2012.

Access to Medicine Index 2010Results: measuring and comparing

3. How to score performance for the companies for which data is not available?• Companies were scored significantly less (where analysts did

not have robust data), but initiatives were reflected qualitatively for learning purposes.

• Scoring of performance and [buisness model] innovations were based on the following:– Inputs– Process– Targets– Outputs – most sought by the Index & stakeholders

• Index aims to be a driver for better disclosure and reporting of initatives

Focus of Innovation indicators

Access to Medicine Index 2010Results: measuring and comparing

4. How to analyse and compare data provided by the companies that comes in different units and structures?

Index is a relative assessment tool, comparability of data is necessary but can present a major challenge, such as:

a) Differences in geographical breakdown of revenue.EMEA and RoW (mix developed and developing) are prevalent over World Bank or UN definitions.

b) Differences in definition & calculations of ‘price’ / ‘value’.Weak disclosure of – and variability in – ‘cost’ definition. Prices & definition of tiers use ‘relative’ [western] benchmark

c) Differences in measurement approach to ‘supply volume’.Key output measure: supply units, vol. active ingredient, Tx-doses, vials of product, or patients reached.

Access to Medicine Index 2010Results: measuring and comparing

5. How to take into consideration the actual impact of company programs on relieving social burden?

Challenges remain which compound reliable measurement: • Low and ad hoc disclosure by companies (& other groups)• Lack of harmonised measures • Multiplicity of factors external to companies

Measurement is important for reasons such as:• Reliable proof of their impact on health burden acceptable to

all stakeholders. • That competition between companies on access is on

indicators that matter to situation on the ground.

Access to Medicine Index 2010Conclusions

Index hopes to progressively address many of the challenges presented to improve the assessment and comparison: • Short-term: Some challenges (such as correlation of indicators) we

are taking steps to address ahead of Index 2012.• Longer-term: Index can be a facilitator of greater – and more meaningful

– data disclosure, performance, business model innovation and data harmonisation. BUT will take time & a collective effort.

Additionally the Index hopes:• To inspire further academic research in the area....• To build a better understanding of how it is motivating change

within the pharmaceutical companies ….• It’s implications and learnings are diffused accross-s

ector (measure social component of other businesses)....

Access to Medicine Index 2010The Final Ranking….

15

Daiichi Sankyo Co. Ltd. 20Astellas Pharma Inc. 19

Takeda Pharmaceutical Co. 18Merck KGaA 17Eisai Co. Ltd. 16

Bristol-Myers Squibb Co. 15Bayer AG 14

Eli Lilly & Co. 13Boehringer-Ingelheim 12

Pfizer Inc. 11Abbott Laboratories Inc. 10

Johnson & Johnson 9Novo Nordisk A/S 8AstraZeneca PLC 7

Roche Holdings Ltd. 6Sanofi-Aventis 5

Gilead Sciences 4Novartis AG 3

Merck & Co. Inc. 2GlaxoSmithKline PLC 1

0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5

Management Public Policy R&D Pricing Patents Capability Donations & Philanthropy

16

General Enquiries: info@atmindex.org Technical Enquiries: sedwards@atmindex.org

More Information! www.atmindex.org